FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 349:146-153 July 10, 2003 Number 2 Next

	Full Text PDF PDA Full Text PowerPoint Slide Set Perspective by Bick, R. L. Letters Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited E-mail When Letters Appear PubMed Citation

ABSTRACT

Background Patients with cancer have a substantial risk of recurrent thrombosis despite the use of oral anticoagulant therapy. We compared the efficacy of a low-molecular-weight heparin with that of an oral anticoagulant agent in preventing recurrent thrombosis in patients with cancer.

Methods Patients with cancer who had acute, symptomatic proximal deep-vein thrombosis, pulmonary embolism, or both were randomly assigned to receive low-molecular-weight heparin (dalteparin) at a dose of 200 IU per kilogram of body weight subcutaneously once daily for five to seven days and a coumarin derivative for six months (target international normalized ratio, 2.5) or dalteparin alone for six months (200 IU per kilogram once daily for one month, followed by a daily dose of approximately 150 IU per kilogram for five months).

Results During the six-month study period, 27 of 336 patients in the dalteparin group had recurrent venous thromboembolism, as compared with 53 of 336 patients in the oral-anticoagulant group (hazard ratio, 0.48; P=0.002). The probability of recurrent thromboembolism at six months was 17 percent in the oral-anticoagulant group and 9 percent in the dalteparin group. No significant difference between the dalteparin group and the oral-anticoagulant group was detected in the rate of major bleeding (6 percent and 4 percent, respectively) or any bleeding (14 percent and 19 percent, respectively). The mortality rate at six months was 39 percent in the dalteparin group and 41 percent in the oral-anticoagulant group.

Conclusions In patients with cancer and acute venous thromboembolism, dalteparin was more effective than an oral anticoagulant in reducing the risk of recurrent thromboembolism without increasing the risk of bleeding.

Source Information

From the Departments of Medicine (A.Y.Y.L., M.N.L.) and Clinical Epidemiology and Biostatistics (M.N.L., J.A.J., S.H., M.G.), McMaster University, Hamilton, Ont., Canada; Henderson Research Centre, Hamilton Health Sciences and McMaster University, Hamilton, Ont., Canada (M.N.L., J.A.J., S.H., M.G.); the Department of Medicine, University of Western Australia, Perth, Australia (R.I.B.); Pharmacia Corporation, Peapack, N.J. (C.B.); the Department of Surgical Oncology and Technology, Imperial College, London (A.K.K.); Academic Hospital Maastricht, Maastricht, the Netherlands (M.P.); the Department of Medicine and Pediatrics, George Washington University, Washington, D.C. (F.R.R.); and the Department of Medicine, University of Western Ontario, London, Ont., Canada (M.J.K.).

Address reprint requests to Dr. Levine at Hamilton Health Sciences, Henderson Hospital, Rm. 9, 90 Wing, 711 Concession St., Hamilton, ON L8V 1C3, Canada.

Full Text of this Article

Related Letters:

Dalteparin Compared with an Oral Anticoagulant for Thromboprophylaxis in Patients with Cancer
Blot E., Gutman F., Thannberger A., Hull J. H.K., Hull P. J., Kaufman J. L., Nader F., Lee A. Y.Y., Levine M. N., Gent M., Bick R. L.
Extract | Full Text | PDF  
N Engl J Med 2003; 349:1385-1387, Oct 2, 2003. Correspondence

This article has been cited by other articles:

• Khorana, A. A. (2009). Cancer and thrombosis: implications of published guidelines for clinical practice. Ann Oncol 0: mdp068v1-mdp068 [Abstract] [Full Text]  
• Barginear, M. F., Lesser, M., Akerman, M. L., Strakhan, M., Shapira, I., Bradley, T., Budman, D. R. (2009). Need for Inferior Vena Cava Filters in Cancer Patients: A Surrogate Marker for Poor Outcome. CLIN APPL THROMB HEMOST 15: 263-269 [Abstract]  
• Nutescu, E. A, Spinler, S. A, Wittkowsky, A., Dager, W. E (2009). Low-Molecular-Weight Heparins in Renal Impairment and Obesity: Available Evidence and Clinical Practice Recommendations Across Medical and Surgical Settings. The Annals of Pharmacotherapy 43: 1064-1083 [Abstract] [Full Text]  
• Squizzato, A., Galli, M., Dentali, F., Ageno, W. (2009). Outpatient treatment and early discharge of symptomatic pulmonary embolism: a systematic review. Eur Respir J 33: 1148-1155 [Abstract] [Full Text]  
• Mandala, M., Falanga, A., Roila, F., On behalf of the ESMO Guidelines Working Group, (2009). Management of venous thromboembolism in cancer patients: ESMO Clinical Recommendations. Ann Oncol 20: iv182-iv184 [Full Text]  
• MICKELSON, D., MADY, E. N., TENG, K. (2009). A 43-year-old woman with chest pressure. Cleveland Clinic Journal of Medicine 76: 191-198 [Full Text]  
• Zhu, T., Martinez, I., Emmerich, J. (2009). Venous Thromboembolism: Risk Factors for Recurrence. Arterioscler. Thromb. Vasc. Bio. 29: 298-310 [Abstract] [Full Text]  
• Sousou, T., Khorana, A. A. (2009). New Insights Into Cancer-Associated Thrombosis. Arterioscler. Thromb. Vasc. Bio. 29: 316-320 [Abstract] [Full Text]  
• BABU, B., CARMAN, T. L. (2009). Cancer and clots: All cases of venous thromboembolism are not treated the same. Cleveland Clinic Journal of Medicine 76: 129-135 [Abstract] [Full Text]  
• Lee, A. Y.Y. (2009). Treatment of Venous Thromboembolism in Patients with Cancer. Am Soc Clin Oncol Ed Book 2009: 331-336 [Abstract] [Full Text]  
• Fareed, J., Jeske, W., Fareed, D., Clark, M., Wahi, R., Adiguzel, C., Hoppensteadt, D. (2008). Are All Low Molecular Weight Heparins Equivalent in the Management of Venous Thromboembolism?. CLIN APPL THROMB HEMOST 14: 385-392 [Abstract]  
• Mori, A., Ibata, M., Mashiko, S., Tsutsumi, Y., Masauzi, N., Hashino, S., Morioka, M., Asaka, M., Imamura, M. (2008). Long-Term Administration of a Low-Molecular-Weight Heparin Contributed to Successful Treatment in a Patient With Primary Mediastinal Large B-Cell Lymphoma and Venous Thromboembolism. CLIN APPL THROMB HEMOST 14: 468-471 [Abstract]  
• Authors/Task Force Members, , Torbicki, A., Perrier, A., Konstantinides, S., Agnelli, G., Galie, N., Pruszczyk, P., Bengel, F., Brady, A. J.B., Ferreira, D., Janssens, U., Klepetko, W., Mayer, E., Remy-Jardin, M., Bassand, J.-P., ESC Committee for Practice Guidelines (CPG), , Vahanian, A., Camm, J., De Caterina, R., Dean, V., Dickstein, K., Filippatos, G., Funck-Brentano, C., Hellemans, I., Kristensen, S. D., McGregor, K., Sechtem, U., Silber, S., Tendera, M., Widimsky, P., Zamorano, J. L., Document Reviewers, , Zamorano, J.-L., Andreotti, F., Ascherman, M., Athanassopoulos, G., De Sutter, J., Fitzmaurice, D., Forster, T., Heras, M., Jondeau, G., Kjeldsen, K., Knuuti, J., Lang, I., Lenzen, M., Lopez-Sendon, J., Nihoyannopoulos, P., Perez Isla, L., Schwehr, U., Torraca, L., Vachiery, J.-L. (2008). Guidelines on the diagnosis and management of acute pulmonary embolism: The Task Force for the Diagnosis and Management of Acute Pulmonary Embolism of the European Society of Cardiology (ESC). Eur Heart J 29: 2276-2315 [Full Text]  
• Carrier, M., Le Gal, G., Wells, P. S., Fergusson, D., Ramsay, T., Rodger, M. A. (2008). Systematic Review: The Trousseau Syndrome Revisited: Should We Screen Extensively for Cancer in Patients with Venous Thromboembolism?. ANN INTERN MED 149: 323-333 [Abstract] [Full Text]  
• Ornstein, D. L. (2008). A Nickel's Worth of Cancer. ANN INTERN MED 149: 350-352 [Full Text]  
• Prandoni, P., Trujillo-Santos, J., Surico, T., Valle, F. D., Piccioli, A., Monreal, M., for the RIETE Investigators, (2008). Recurrent thromboembolism and major bleeding during oral anticoagulant therapy in patients with solid cancer: findings from the RIETE registry. haematol 93: 1432-1434 [Full Text]  
• Wen, P. Y., Kesari, S. (2008). Malignant Gliomas in Adults. NEJM 359: 492-507 [Full Text]  
• Schulman, S., Beyth, R. J., Kearon, C., Levine, M. N. (2008). Hemorrhagic Complications of Anticoagulant and Thrombolytic Treatment: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 133: 257S-298S [Abstract] [Full Text]  
• Kearon, C., Kahn, S. R., Agnelli, G., Goldhaber, S., Raskob, G. E., Comerota, A. J. (2008). Antithrombotic Therapy for Venous Thromboembolic Disease: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 133: 454S-545S [Abstract] [Full Text]  
• Bates, S. M., Greer, I. A., Pabinger, I., Sofaer, S., Hirsh, J. (2008). Venous Thromboembolism, Thrombophilia, Antithrombotic Therapy, and Pregnancy: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 133: 844S-886S [Abstract] [Full Text]  
• Monagle, P., Chalmers, E., Chan, A., deVeber, G., Kirkham, F., Massicotte, P., Michelson, A. D. (2008). Antithrombotic Therapy in Neonates and Children: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 133: 887S-968S [Abstract] [Full Text]  
• Groce, J. B. (2008). Initial management of deep venous thrombosis in the outpatient setting. Am J Health Syst Pharm 65: 866-874 [Full Text]  
• Kierner, K. A., Gartner, V., Schwarz, M., Watzke, H. H. (2008). Use of Thromboprophylaxis in Palliative Care Patients: A Survey Among Experts in Palliative Care, Oncology, Intensive Care, and Anticoagulation. AM J HOSP PALLIAT CARE 25: 127-131 [Abstract]  
• Brown, E. N., Herrington, J. D. (2008). Review of the Relationship Between Venous Thromboembolism, Malignancy and Its Treatment. Journal of Pharmacy Practice 21: 126-137 [Abstract]  
• Smeglin, A., Ansari, M., Skali, H., Oo, T. H., Maysky, M. (2008). Marantic Endocarditis and Disseminated Intravascular Coagulation With Systemic Emboli in Presentation of Pancreatic Cancer. JCO 26: 1383-1385 [Full Text]  
• Tapson, V. F. (2008). Acute Pulmonary Embolism. NEJM 358: 1037-1052 [Full Text]  
• Nguyen, D., Lee, S.-J., Libby, E., Verschraegen, C. (2008). Rate of Thromboembolic Events in Mesothelioma. Ann. Thorac. Surg. 85: 1032-1038 [Abstract] [Full Text]  
• Gross, P. L., Weitz, J. I. (2008). New Anticoagulants for Treatment of Venous Thromboembolism. Arterioscler. Thromb. Vasc. Bio. 28: 380-386 [Abstract] [Full Text]  
• Imberti, D., Agnelli, G., Ageno, W., Moia, M., Palareti, G., Pistelli, R., Rossi, R., Verso, M., for the MASTER Investigators, (2008). Clinical characteristics and management of cancer-associated acute venous thromboembolism: findings from the MASTER Registry. haematol 93: 273-278 [Abstract] [Full Text]  
• Spyropoulos, A. C. (2008). Outpatient-Based Primary and Secondary Thromboprophylaxis With Low-Molecular-Weight Heparin. CLIN APPL THROMB HEMOST 14: 63-74 [Abstract]  
• Falanga, A., Lee, A. Y. Y., Streiff, M. B., Lyman, G. H. (2008). Anticoagulation in the Treatment of Venous Thromboembolism in Patients with Cancer. Am Soc Clin Oncol Ed Book 2008: 258-268 [Abstract] [Full Text]  
• Lyman, G. H., Khorana, A. A., Falanga, A., Clarke-Pearson, D., Flowers, C., Jahanzeb, M., Kakkar, A., Kuderer, N. M., Levine, M. N., Liebman, H., Mendelson, D., Raskob, G., Somerfield, M. R., Thodiyil, P., Trent, D., Francis, C. W. (2007). American Society of Clinical Oncology Guideline: Recommendations for Venous Thromboembolism Prophylaxis and Treatment in Patients With Cancer. JCO 25: 5490-5505 [Abstract] [Full Text]  
• Asopa, S., Patel, A., Khan, O. A., Sharma, R., Ohri, S. K. (2007). Non-bacterial thrombotic endocarditis. Eur. J. Cardiothorac. Surg. 32: 696-701 [Abstract] [Full Text]  
• Hostettler, N., Naggi, A., Torri, G., Ishai-Michaeli, R., Casu, B., Vlodavsky, I., Borsig, L. (2007). P-selectin- and heparanase-dependent antimetastatic activity of non-anticoagulant heparins. FASEB J. 21: 3562-3572 [Abstract] [Full Text]  
• Noble, S (2007). The challenges of managing cancer related venous thromboembolism in the palliative care setting. Postgrad. Med. J. 83: 671-674 [Abstract] [Full Text]  
• Khorana, A. A. (2007). The NCCN Clinical Practice Guidelines on Venous Thromboembolic Disease: Strategies for Improving VTE Prophylaxis in Hospitalized Cancer Patients. The Oncologist 12: 1361-1370 [Abstract] [Full Text]  
• Garcia, D. A., Khamashta, M. A., Crowther, M. A. (2007). How we diagnose and treat thrombotic manifestations of the antiphospholipid syndrome: a case-based review. Blood 110: 3122-3127 [Abstract] [Full Text]  
• Mandala, M., Reni, M., Cascinu, S., Barni, S., Floriani, I., Cereda, S., Berardi, R., Mosconi, S., Torri, V., Labianca, R. (2007). Venous thromboembolism predicts poor prognosis in irresectable pancreatic cancer patients. Ann Oncol 18: 1660-1665 [Abstract] [Full Text]  
• Loberg, R. D., Bradley, D. A., Tomlins, S. A., Chinnaiyan, A. M., Pienta, K. J. (2007). The Lethal Phenotype of Cancer: The Molecular Basis of Death Due to Malignancy. CA Cancer J Clin 57: 225-241 [Abstract] [Full Text]  
• Nishioka, J., Goodin, S. (2007). Low-molecular-weight heparin in cancer-associated thrombosis: treatment, secondary prevention, and survival. J Oncol Pharm Pract 13: 85-97 [Abstract]  
• Nutescu, E. A. (2007). Assessing, preventing, and treating venous thromboembolism: Evidence-based approaches. Am J Health Syst Pharm 64: S5-S13 [Abstract] [Full Text]  
• De Caterina, R., Husted, S., Wallentin, L., Agnelli, G., Bachmann, F., Baigent, C., Jespersen, J., Kristensen, S. D., Montalescot, G., Siegbahn, A., Verheugt, F. W.A., Weitz, J. (2007). Anticoagulants in heart disease: current status and perspectives. Eur Heart J 0: ehl492v1-34 [Full Text]  
• Meyer, G (2007). Does low-molecular-weight heparin influence cancer-related mortality?. Ann Oncol 18: 609-610 [Full Text]  
• Segal, J. B., Streiff, M. B., Hofmann, L. V., Thornton, K., Bass, E. B. (2007). Management of Venous Thromboembolism: A Systematic Review for a Practice Guideline. ANN INTERN MED 146: 211-222 [Abstract] [Full Text]  
• Snow, V., Qaseem, A., Barry, P., Hornbake, E. R., Rodnick, J. E., Tobolic, T., Ireland, B., Segal, J., Bass, E., Weiss, K. B., Green, L., Owens, D. K., The Joint American College Of Physicians/american, (2007). Management of Venous Thromboembolism: A Clinical Practice Guideline from the American College of Physicians and the American Academy of Family Physicians. Ann Fam Med 5: 74-80 [Abstract] [Full Text]  
• Bates, S. M. (2007). Management of Pregnant Women with Thrombophilia or a History of Venous Thromboembolism. ASH Education Book 2007: 143-150 [Abstract] [Full Text]  
• Falanga, A., Rickles, F. R. (2007). Management of Thrombohemorrhagic Syndromes (THS) in Hematologic Malignancies. ASH Education Book 2007: 165-171 [Abstract] [Full Text]  
• Goldhaber, S. Z., Berkwits, M. (2006). Trials That Matter: Can Patients with Venous Thromboembolism Be Treated with Fixed-Dose Subcutaneous Unfractionated Heparin?. ANN INTERN MED 145: 929-931 [Full Text]  
• Ferretti, G., Bria, E., Giannarelli, D., Carlini, P., Felici, A., Mandala, M., Papaldo, P., Fabi, A., Ciccarese, M., Cuppone, F., Cecere, F. L., Nuzzo, C., Terzoli, E., Cognetti, F. (2006). Is Recurrent Venous Thromboembolism After Therapy Reduced by Low-Molecular-Weight Heparin Compared With Oral Anticoagulants?. Chest 130: 1808-1816 [Abstract] [Full Text]  
• Scarvelis, D., Wells, P. S. (2006). Diagnosis and treatment of deep-vein thrombosis.. CMAJ 175: 1087-1092 [Abstract] [Full Text]  
• Deitcher, S. R., Kessler, C. M., Merli, G., Rigas, J. R., Lyons, R. M., Fareed, J. (2006). Secondary Prevention of Venous Thromboembolic Events in Patients With Active Cancer: Enoxaparin Alone Versus Initial Enoxaparin Followed by Warfarin for a 180-Day Period. CLIN APPL THROMB HEMOST 12: 389-396 [Abstract]  
• Ferretti, G, Bria, E, Giannarelli, D, Carlini, P, Felici, A, Mandala, M, Papaldo, P, Fabi, A, Ciccarese, M, Cognetti, F (2006). Does low-molecular-weight heparin influence cancer-related mortality?. Ann Oncol 17: 1604-1606 [Full Text]  
• Fennerty, A (2006). Venous thromboembolic disease and cancer.. Postgrad. Med. J. 82: 642-648 [Abstract] [Full Text]  
• Costenbader, K. H., Fidias, P., Gilman, M. D., Qureshi, A., Tambouret, R. H. (2006). Case records of the Massachusetts General Hospital. Weekly clinicopathological exercises. Case 29-2006. A 43-year-old woman with painful nodules on the fingertips, shortness of breath, and fatigue.. NEJM 355: 1263-1272 [Full Text]  
• Nutescu, E. A, Wittkowsky, A. K, Dobesh, P. P, Hawkins, D. W, Dager, W. E (2006). Choosing the Appropriate Antithrombotic Agent for the Prevention and Treatment of VTE: A Case-Based Approach. The Annals of Pharmacotherapy 40: 1558-1570 [Abstract] [Full Text]  
• Kearon, C., Ginsberg, J. S., Julian, J. A., Douketis, J., Solymoss, S., Ockelford, P., Jackson, S., Turpie, A. G., MacKinnon, B., Hirsh, J., Gent, M., for the Fixed-Dose Heparin (FIDO) Investigators, (2006). Comparison of fixed-dose weight-adjusted unfractionated heparin and low-molecular-weight heparin for acute treatment of venous thromboembolism.. JAMA 296: 935-942 [Abstract] [Full Text]  
• Piazza, G., Goldhaber, S. Z. (2006). Acute Pulmonary Embolism: Part II: Treatment and Prophylaxis. Circulation 114: e42-e47 [Full Text]  
• Adess, M., Eisner, R., Nand, S., Godwin, J., Messmore, H. L. Jr, Wehrmacher, W. H. (2006). Thromboembolism in Cancer Patients: Pathogenesis and Treatment. CLIN APPL THROMB HEMOST 12: 254-266 [Abstract]  
• Gerber, D. E., Grossman, S. A., Streiff, M. B. (2006). Management of Venous Thromboembolism in Patients With Primary and Metastatic Brain Tumors. JCO 24: 1310-1318 [Abstract] [Full Text]  
• Kroger, K., Weiland, D., Ose, C., Neumann, N., Weiss, S., Hirsch, C., Urbanski, K., Seeber, S., Scheulen, M. E. (2006). Risk factors for venous thromboembolic events in cancer patients. Ann Oncol 17: 297-303 [Abstract] [Full Text]  
• Robinson, G. V (2006). Pulmonary embolism in hospital practice. BMJ 332: 156-160 [Full Text]  
• Prandoni, P. (2005). How I treat venous thromboembolism in patients with cancer. Blood 106: 4027-4033 [Abstract] [Full Text]  
• Goodin, S. (2005). Selecting an anticoagulant for recurrent venous thromboembolism in cancer. Am J Health Syst Pharm 62: S10-S13 [Abstract] [Full Text]  
• Kucher, N., Quiroz, R., McKean, S., Sasahara, A. A, Goldhaber, S. Z (2005). Extended enoxaparin monotherapy for acute symptomatic pulmonary embolism. Vasc Med 10: 251-256 [Abstract]  
• Levine, M. N., Lee, A. Y.Y., Kakkar, A. K. (2005). In Reply:. JCO 23: 7250-7250 [Full Text]  
• Ferretti, G., Bria, E., Giannarelli, D., Carlini, P., Felici, A., Mandala, M., Papaldo, P., Nistico, C., Fabi, A., Cuppone, F., Gelibter, A., Terzoli, E., Cognetti, F. (2005). Low-Molecular-Weight Heparin Versus Oral Anticoagulant Therapy for the Long-Term Treatment of Symptomatic Venous Thromboembolism: Is There Any Difference in Cancer-Related Mortality?. JCO 23: 7248-7250 [Full Text]  
• Ansell, J. (2005). Vena Cava Filters: Do We Know All That We Need to Know?. Circulation 112: 298-299 [Full Text]  
• Borowski, A., Ghodsizad, A., Cohnen, M., Gams, E. (2005). Recurrent Embolism in the Course of Marantic Endocarditis. Ann. Thorac. Surg. 79: 2145-2147 [Abstract] [Full Text]  
• Falanga, A., Zacharski, L. (2005). Deep vein thrombosis in cancer: the scale of the problem and approaches to management. Ann Oncol 16: 696-701 [Abstract] [Full Text]  
• Noble, S. I., Finlay, I G (2005). Is long-term low-molecular-weight heparin acceptable to palliative care patients in the treatment of cancer related venous thromboembolism? A qualitative study. Palliat Med 19: 197-201 [Abstract]  
• Lee, A. Y.Y., Rickles, F. R., Julian, J. A., Gent, M., Baker, R. I., Bowden, C., Kakkar, A. K., Prins, M., Levine, M. N. (2005). Randomized Comparison of Low Molecular Weight Heparin and Coumarin Derivatives on the Survival of Patients With Cancer and Venous Thromboembolism. JCO 23: 2123-2129 [Abstract] [Full Text]  
• Haines, S. T., Nutescu, E. A. (2005). Current and emerging treatment options for venous thrombosis: A case discussion. Am J Health Syst Pharm 62: 593-605 [Full Text]  
• Goldhaber, S. Z. (2005). Tamoxifen: Preventing Breast Cancer and Placing the Risk of Deep Vein Thrombosis in Perspective. Circulation 111: 539-541 [Full Text]  
• Pineo, G. F., Hull, R. D. (2005). Low-Molecular-Weight Heparin for the Treatment of Venous Thromboembolism in the Elderly. CLIN APPL THROMB HEMOST 11: 15-23 [Abstract]  
• Zacharski, L. R., Prandoni, P., Monreal, M. (2005). Warfarin Versus Low-Molecular-Weight Heparin Therapy in Cancer Patients. The Oncologist 10: 72-79 [Abstract] [Full Text]  
• Wittkowsky, A. K. (2004). Anticoagulation in Hypercoagulable Conditions: Special Considerations in the Treatment and Prevention of Venous Thromboembolism. Journal of Pharmacy Practice 17: 308-316 [Abstract]  
• Levine, M. N., Raskob, G., Beyth, R. J., Kearon, C., Schulman, S. (2004). Hemorrhagic Complications of Anticoagulant Treatment: The Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 126: 287S-310S [Abstract] [Full Text]  
• Buller, H. R., Agnelli, G., Hull, R. D., Hyers, T. M., Prins, M. H., Raskob, G. E. (2004). Antithrombotic Therapy for Venous Thromboembolic Disease: The Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 126: 401S-428S [Abstract] [Full Text]  
• Bates, S. M., Greer, I. A., Hirsh, J., Ginsberg, J. S. (2004). Use of Antithrombotic Agents During Pregnancy: The Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 126: 627S-644S [Abstract] [Full Text]  
• McRae, S. J., Ginsberg, J. S. (2004). Initial Treatment of Venous Thromboembolism. Circulation 110: I-3-I-9 [Abstract] [Full Text]  
• Kearon, C. (2004). Long-Term Management of Patients After Venous Thromboembolism. Circulation 110: I-10-I-18 [Abstract] [Full Text]  
• Weitz, J. I. (2004). New Anticoagulants for Treatment of Venous Thromboembolism. Circulation 110: I-19-I-26 [Abstract] [Full Text]  
• Elting, L. S., Escalante, C. P., Cooksley, C., Avritscher, E. B. C., Kurtin, D., Hamblin, L., Khosla, S. G., Rivera, E. (2004). Outcomes and Cost of Deep Venous Thrombosis Among Patients With Cancer. Arch Intern Med 164: 1653-1661 [Abstract] [Full Text]  
• Castelli, R., Porro, F., Tarsia, P. (2004). The heparins and cancer: review of clinical trials and biological properties. Vasc Med 9: 205-213 [Abstract]  
• Bates, S. M., Ginsberg, J. S. (2004). Treatment of Deep-Vein Thrombosis. NEJM 351: 268-277 [Full Text]  
• Errichi, B. M., Cesarone, M. R., Belcaro, G., Marinucci, R., Ricci, A., Ippolito, A., Brandolini, R., Vinciguerra, G., Dugall, M., Felicita, A., Pellegrini, L., Gizzi, G., Ruffini, M., Acerbi, G., Bavera, P., Di Renzo, A., Corsi, M., Scoccianti, M., Hosoi, M., Lania, M. (2004). Prevention of Recurrent Deep Venous Thrombosis with Sulodexide: The SanVal Registry. ANGIOLOGY 55: 243-249 [Abstract]  
• Bergamaschini, L., Rossi, E., Storini, C., Pizzimenti, S., Distaso, M., Perego, C., De Luigi, A., Vergani, C., Grazia De Simoni, M. (2004). Peripheral Treatment with Enoxaparin, a Low Molecular Weight Heparin, Reduces Plaques and {beta}-Amyloid Accumulation in a Mouse Model of Alzheimer's Disease. J. Neurosci. 24: 4181-4186 [Abstract] [Full Text]  
• Vaknansky, A., Kupfer, Y., Tessler, S., Boger, C., Schroll, S., Holmer, S., Schulman, S., Eriksson, H. (2004). Ximelagatran for Secondary Prevention of Venous Thromboembolism. NEJM 350: 618-619 [Full Text]  
• Quinlan, D. J., McQuillan, A., Eikelboom, J. W. (2004). Low-Molecular-Weight Heparin Compared with Intravenous Unfractionated Heparin for Treatment of Pulmonary Embolism: A Meta-Analysis of Randomized, Controlled Trials. ANN INTERN MED 140: 175-183 [Abstract] [Full Text]  
• (2004). ADDITIONAL ARTICLES ABSTRACTED IN ACP JOURNAL CLUB. Evid. Based Med. 9: 3-3 [Full Text]  
• (2004). Other articles noted: 25 Jul 03 to 7 Nov 03. Evid. Based Nurs. 7: e1-1 [Full Text]